pre-update Archives

On-Demand Webinar

新兴生物技术公司资产评估简介

Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…

Jim Gallagher2021 年 1 月 21 日

White Paper

“要从哪里开始？”：选择首次人体临床试验的起始剂量

This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…

Jim Gallagher2020 年 12 月 22 日

Publication

The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries

Alison Dillman,1 Michael J Zoratti,2 Jay JH Park,3 Grace Hsu,2 Louis Dron,2 Gerald Smith,2 Ofir Harari,2 Craig R Rayner,4 Noor-E Zannat,2 Alind Gupta,2 Eric Mackay,5 Paul…

Jim Gallagher2020 年 12 月 22 日

Blog

Be Honest, Be Reliable, Be Human: Insights from a Global Drug Development Expert

One of the most exciting things about working in the pharmaceutical industry is the ability…

Certara2020 年 12 月 16 日

Press Release

Certara Announces Pricing of its Upsized Initial Public Offering

PRINCETON, NJ.— 2020 年 12 月 10 日 – Certara, Inc. (“Certara”), a global leader in biosimulation, today…

Certara2020 年 12 月 10 日

Article

Certara’s Phoenix software supports training of the next generation of the pharmacometricians in China

The Pharmacy department of the Shanghai Chest Hospital is dedicated to developing and applying model-informed…

Certara2020 年 12 月 3 日

On-Demand Webinar

根据机制性模型发现和开发用于免疫肿瘤学的双特异性抗体：探戈需要 2 人配合

More than 50 bispecific antibodies are in oncology clinical development with a large diversity in…

Certara2020 年 12 月 2 日

Brochure

BaseCase Market Access

Certara2020 年 11 月 30 日

Article

Getting Real with RWE

By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…

Certara2020 年 11 月 20 日

Blog

Regulatory submissions and transactions with Health Canada

By Robert Labriola We’ve seen recent trends and activity with regards to pharmaceutical regulatory submissions…

Certara2020 年 11 月 19 日

pre-update